Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT05730608
Overview
Purpose To investigate the ability of 18F-FDG PET/CT imaging to detect metastases not detected by conventional imaging (CT and bone scintigraphy) in patients diagnosed with stage II/III and locoregional recurrent breast cancer (BC) which can affect the choice of treatment. Hypothesis The hypothesis is that 18F-FDG PET/CT can provide information about disease stage beyond the currently used conventional imaging (CT and bone scintigraphy) in patients diagnosed with stage II/III or locoregional recurrent BC. Objectives
Sponsor
Vestre Viken Hospital Trust
Phase
N/A
Contacts
Harald Grut, MD, PHD (Principal Investigator)
harald.grut@gmail.com
004797108503
ClinicalTrials.gov
NCT05730608Drug / Compound
Help us improve your experience